Home › Funds › ORBIMED ADVISORS LLC › MLYS

ORBIMED ADVISORS LLC position in MLYS

MINERALYS THERAPEUTICS INC · Health Care

ORBIMED ADVISORS LLC reported holding 2,110,300 shares of MLYS (MINERALYS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$56.9M, representing 1.14% of its reported portfolio and ranking #25 among its reported holdings. ORBIMED ADVISORS LLC has disclosed MLYS holdings in 9 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)2.11M sh
Reported value held$56.94M
Portfolio Weight1.14%
First reportedQ1 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's MLYS position evolved

ORBIMED ADVISORS LLC first disclosed a stake in MLYS in Q1 2024 at 2,021,424 shares (US$26.1M). The position peaked in Q2 2026 at 2,110,300 shares, worth US$56.9M. Across 9 filings, ORBIMED ADVISORS LLC increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 2,110,300 shares valued at US$56.9M — an increase of 57,400 shares quarter over quarter.. Notable position changes include a 93% increase in Q3 2025 (shares fell 4% over the following quarter), a 33% trim in Q4 2025 (shares fell 25% over the following quarter), a 109% increase in Q1 2026 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 2.02M $26.10M New
Q2 2024 2.02M $23.65M Hold
Q3 2024 2.00M $24.26M Reduce
Q4 2024 1.61M $19.84M Reduce
Q2 2025 760.35K $10.29M New
Q3 2025 1.47M $55.72M Add
Q4 2025 980.40K $35.58M Reduce
Q1 2026 2.05M $55.61M Add
Q2 2026 2.11M $56.94M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MLYS and 13F data

MLYS (MINERALYS THERAPEUTICS INC) is a Health Care company. 53 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MLYS

All MLYS fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held MLYS?

ORBIMED ADVISORS LLC has disclosed MLYS holdings in 9 of the last 10 reported quarters, going back to Q1 2024.

What is ORBIMED ADVISORS LLC's current position in MLYS?

As of Q2 2026, ORBIMED ADVISORS LLC holds 2.11M shares of MLYS (MINERALYS THERAPEUTICS INC), valued at $56.94M, representing 1.14% of its reported portfolio and ranking #25.

Has ORBIMED ADVISORS LLC been buying or selling MLYS?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in MLYS. The position peaked in Q2 2026 at 2.11M shares.

Which other funds hold MLYS?

Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Catalys Pacific, LLC, Samsara BioCapital, LLC, among 53 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.